BioSpace News Archive

T2 Biosystems, Inc. announced that the Nasdaq Hearings Panel has granted the Company’s request for an extension until November 1, 2022, to regain compliance with Nasdaq’s minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), today announced that the rationale and plans for its upcoming Phase 3 ZILO-301 (zilovertamab plus ibrutinib targeting ROR1 for patients with Mantle Cell Lymphoma) clinical trial will be highlighted in a poster presentation at the European Hematology Association (EHA) 2022 Hybrid Congress.

Kintara Therapeutics, Inc. announced that President and CEO Robert E. Hoffman will present a corporate overview at the JMP Securities Life Sciences Conference.

Minimally invasive image-guided therapy company, SpinaFX Medical Inc. (SpinaFX), today announced it will exhibit at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting in Boston, MA, June 11-16, at booth 414.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that its board of directors has adopted a limited-duration shareholder rights plan.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that management will participate in the Sidoti Small Cap Virtual Investor Conference on Wednesday, June 15, 2022.

The Lupus Research Alliance, the world’s leading private funder of lupus research, announced inaugural recipients of Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research.

For over 40 years, COPAN, a global leader in pre-analytics has helped to shape the standard for excellence in Clinical Microbiology with innovative sample collection and transport systems and cutting-edge solutions for laboratory automation and artificial intelligence.

XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate drug was presented at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9th-12th.

The U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency’s recent increased flexibilities.